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Abstract 
Type 2 diabetes mellitus (T2DM) is characterized by hyperglycemia that can occur through 
mechanisms such as; impaired insulin secretion, insulin resistance in peripheral tissues and 
increased glucose output by liver. Type 2 diabetes clearly represents a multifactorial disease, 
and several findings indicate that multiple genetic and environmental factors are important 
contributing factor involved in the pathogenesis of this disease. Recently great emphasis has 
been given to genetical factors to combat the disease. The discovery of T2DM-associated 
genes through genome wide association studies (GWAS) has provided insight into the genetic 
architecture of T2DM, and several genes have been reported to be related to T2DM 
susceptibility. One of these genes is PPARG -γ2 (Peroxisome proliferator-activated receptors 
–gamma), which has been confirmed to be a potential type 2 diabetic risk for different ethnic 
populations. It has been reported in the literature that, at the molecular level, PPAR-γ2Pro12 
Ala gene polymorphism; the Pro allele has been associated with increased risk of diabetic 2 in 
different population. On the other hand, the Ala allele of the PPAR-γ2 gene has been reported 
to be strongly associated with reduced risk of the disease. The aim of the present study was to 
assess the impact of PPAR-γ2 gene polymorphism on risk of diabetic type 2 patients visiting 
Gondar University Teaching Hospital. One hundred diabetic-2 patients and an equal number 
of age and sex matched control groups were recruited for this case control study from the 
teaching hospital of the university.  
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INTRODUCTION  
Type 2 diabetes is an increasingly common, 
serious metabolic disorder with a substantial 
inherited component. It is characterized by 
defects in both insulin secretion and action. 
Progress in identification of specific genetic 
variants predisposing to the disease has been 
limited. Type 2 diabetes is a serious metabolic 
disease associated with an increased risk of 
premature death and substantial disability, 
largely mediated through its adverse effects on 
the vasculature. The prevalence of the disease 
is increasing, and the World Health 
organization estimate suggests that by 2025 
there will be 300 million affected individuals 
worldwide. The disorder is characterized by a 
combination of impaired insulin secretion and 
insulin action, both of which precede and 
predict the onset of disease. Through its 
adverse impact on insulin action, obesity is a 
major risk factor for the disease.  
Although environmental factors, both post- 
and prenatal, play an important role in 
determining the risk of disease, a substantial 
body of evidence supports the notion that 
disease susceptibility is influenced by 
inherited factors [1]. While the molecular basis 
for several uncommon Mendelian forms of 
Type 2 diabetes have been defined [2–4], the 
nature and range of allelic variants conferring 
susceptibility to the more common forms of 
this disorder remain poorly defined. The gene 
PPAR-γ2 has been linked with both positive 
and negative associations in different ethnic 
back grounds.  
 
Studies on the association of the Pro12Ala 
polymorphism of PPAR-γ2 with diabetes have 
revealed extensive population-dependent 
variations. However, association of these 
polymorphisms with T2D and its individual 
components has not been investigated in 
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Ethiopian population. Therefore, this study 
attempts to reveal this polymorphism in north 
Gondar administrative zone. 
 
MATERIALS AND METHODS 
For this case control study 100 clinically 
diagnosed diabetic II male and female patients 
in Gondar University teaching hospitals whose 
age group ranges from 35–60 were recruited. 
An equal number of sex and age matched 
volunteer control groups who are confirmed to 
be free from any kind of disease symptoms 
and free from diabetic 2 through clinical 
diagnosis were also involved in the study from 
the same geographical area. Blood samples of 
study subjects were collected by EDTA coated 
vacutanous tubes and transported to the 
laboratory by ice box and stored in -20 until 
DNA isolation were conducted. DNA was 
isolated by standardized phenol chloroform 
method. Appropriate primers (Forward primer 
5`- CAAGCCCAGTCCTTTCTGTG-3`, and 
Reverse primer 5`- 
AGTGAAGGAATCGCTTTCCG-3`), PCR 
reaction and condition will be utilized to 
amplify the gene PPAR-Y2 by the polymerase 
chain reaction. The enzyme HPA II was used 
to differentiate the pro and Ala alleles by the 
presence and absence of a restriction site 
through the Restriction Fragment Length 
Polymorphism (RFLP) techniques.  The Pcr 
products were analyzed by 2% agarose gel 
electrophoresis. Valuable data regarding study 
subjects such as: Age, sex, family history, 
weight, occupation, inhabitant (Urban vs. 
Rural) were registered by specially designed 
questioner and recorded. The association of 
the pro12 Ala gene polymorphism of PPAR-γ-
gene with risk of diabetic 2 were computed 
with appropriate softwares (SPSS 11.5) and 
EPI-info version 3.1(center for disease control 
and prevention, USA) as per the 
recommendation of WHO. This study was 
approved by the ethical committee of The 
Faculty of Natural and computational 
Sciences. Moreover, informed consents were 
obtained from both cases and controls.  
 
RESULTS  
The demographic characteristics of the study 
subjects are given in Figure 1. The mean age 
among cases was 45+9.8 and it was 43+7.5 in 
controls.  Sixty five percent of cases were 
from urban area and the rest were from rural 
areas. The controls were all from urban area. 
There was no statistically significance 
difference between the age of cases and 
controls (p>0.05). As far as age is concerned 
68% of cases were males. In controls the same 
numbers of males were taken because this 
sample is taken after gender of cases was 
known.  
 
 
Fig. 1: Demographic Characteristics of Study Subjects. 
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The percentages of the three genotypes in 
cases were 77,21 and 2 for Pro/Pro, Pro/Ala, 
Ala/Ala, respectively. In controls it was 72,18 
and 5 percentages for three genotypes, 
respectively (Figure 2). 
 
 
Fig. 2: Genotype Distribution of the Gene ppay-2 Gene in Cases and Controls. 
 
There was statistically significant reduced risk 
of developing Diabetic -2 in those individuals 
who attain the Ala/Ala genotype (p<0.05 
Or=0.80, 95% CI, 0.51–1.17). 
 
DISCUSSION  
Diabetes mellitus is a group of metabolic 
diseases characterized by hyperglycemia 
resulting from defects in insulin secretion, 
insulin action, or both. The chronic 
hyperglycemia of diabetes is associated with 
long-term damage, dysfunction, and failure of 
various organs, especially the eyes, kidneys, 
nerves, heart, and blood vessels. The vast 
majority of cases of diabetes fall into two 
broad etiopathogenetic categories. In one 
category, type I diabetes, the cause is an 
absolute deficiency of insulin secretion. 
Individuals at increased risk of developing this 
type of diabetes can often be identified by 
serological evidence of an autoimmune 
pathologic process occurring in the pancreatic 
islets and by genetic markers. In the other, 
much more prevalent category, type 2 
diabetes, the cause is a combination of 
resistance to insulin action and an inadequate 
compensatory insulin secretory response. In 
the latter category, a degree of hyperglycemia 
sufficient to cause pathologic and functional 
changes in various target tissues, but without 
clinical symptoms, may be present for a long 
period of time before diabetes is detected [5].  
 
This disease (T2DM) is a serious metabolic 
disease associated with an increased risk of 
premature death and substantial disability, 
largely mediated through its adverse effects on 
the vasculature. Prevalence of diabetes in 
adults worldwide was estimated to be 4.0% in 
1995 and to rise to 5.4% by the year 2025. It is 
higher in developed than in developing 
countries. The number of adults with diabetes 
in the world will rise from 135 million in 1995 
to 300 million in the year 2025. The 
prevalence of this disease has increased 
sharply during the past two decades in the 
world and is close to 6% and the World Health 
Organization estimate suggest that by 2025 
there will be 300 million affected individuals 
worldwide [6,7]. The major part of this 
numerical increase will occur in developing 
countries. There will be a 42% increase, from 
51 to 72 million, in the developed countries 
and a 170% increase, from 84 to 228 million, 
in the developing countries. Thus, by the year 
2025, >75% of people with diabetes will 
reside in developing countries, as compared 
with 62% in 1995. In developing countries, the 
majority of people with diabetes are in the age 
group of 45–64 years.  
Impact of PPAR-γ2 pro12Ala Gene Polymorphism                                                                            Nega Berhane  
 
 
RRJoMV (2015) 1-8 © STM Journals 2015. All Rights Reserved                                                               Page 4 
In the developed countries, the majority of 
people with diabetes are aged >65 years. This 
pattern will be accentuated by the year 2025. 
There are more women than men with 
diabetes, especially in developed countries. In 
the future, diabetes will be increasingly 
concentrated in urban areas [8].  
 
Type 2 diabetes mellitus is a complex 
metabolic disease that is caused by insulin 
resistance and β-cell dysfunction. It is 
commonly accepted that type 2 diabetes 
results, on the one hand, from population 
aging and, on the other hand, from adverse 
environmental factors of the modern world 
(i.e., high-caloric diets, physical inactivity, and 
a sedentary lifestyle) which favor the 
development of obesity. In fact, excess body 
weight represents a major risk factor for type 2 
diabetes [9–11]. However, some 10% of type 2 
diabetic patients display normal weight, and 
many obese subjects never develop type 2 
diabetes, indicating that type 2 diabetes is not 
exclusively caused by environmental factors.  
 
In addition, there have been reports that, the 
disease clearly represents a multifactorial 
disease, and several findings indicate that 
genetics is an important contributing factor 
[12,13]. Moreover, the disease has been 
reported to be characterized as polygenic 
disorder and generally could be thought of as a 
syndrome [14]. Over the past 2 years, genome-
wide association scans have transformed the 
genetic landscape of type 2 diabetes 
susceptibility, with the current gene count 
close to 20 [15]. Some of the different genes 
studied to assess the risk of diabetic 2 in 
different ethnic back ground include CAPN10 
(11), SLC2A2 (12) KCNJ 11 (11) and HNF4A 
(13) are among others with positive 
associations.  
 
Preoxisome proliferator-activated receptor 
gamma (PPARγ-2) is a nuclear hormone 
receptor that plays a critical role in regulating 
adipocyte differentiation and the transcription 
of genes that are important for lipogenesis. In 
macrophages, the activated PPAR-γ2 promotes 
the cellular efflux of phospholipids and 
cholesterol in the form of high density 
lipoprotein (HDL) [16,17]. PPAR-γ2 is a key 
modulator of adipogenesis and insulin 
signaling [18]. PPAR-γ2, being a transcription 
factor, modulates the expression of several 
genes such as; adiponectin, leptin and resistin, 
which are involved in fatty acid metabolism, 
glucose homeostasis and insulin sensitivity 
[19]. Resistin is a small cysteine-rich secretory 
protein expressed in adipocytes and 
macrophages. It has been proposed that 
resistin provides a connecting link between 
obesity and insulin resistance [20]. In addition, 
it has also been shown to stimulate several 
pro-infl ammatory cytokines including tumour 
necrosis factor alpha (TNF-α) and interleukin 
twelve (IL-12) [21]. PPAR-γ2 regulates the 
expression of resistin through several PPAR 
response elements (PPREs) present in the 
promoter region of the resistin gene. Since 
PPAR-γ2 are nuclear transcription factors 
regulating multiple genes involved in energy 
production, glucose and lipid metabolism, 
polymorphisms in these receptors may 
influence the pathology of numerous diseases 
including obesity, diabetes, atherosclerosis, 
inflammation and cancer [22].  
 
So far, three different peroxisome proliferator 
activated receptor subtypes has been 
discovered: peroxisome proliferator-activated 
receptor-alpha, peroxisome proliferator-
activated receptor-beta, and peroxisome 
proliferator-activated receptor-gamma (PPAR-
γ2), have been identified [23,24]. The human 
PPAR- γ2 gene is located on chromosome 
3p25 and plays critical roles in regulating lipid 
metabolism, adipocyte differentiation, 
proliferation and insulin sensitivity [25]. 
PPAR-γ2 has been shown to have roles in 
regulating genes involved in control of, 
uptake, transport, storage, and disposal of 
lipids, such as lipoprotein lipase, fatty acid 
transport protein, CD36, and adipophilin apart 
from involving in regulating glucose 
metabolism [25]. PPAR-γ2 also plays a key 
role in the entraining of adipose tissue lipid 
metabolism to nutritional state [26]. The 
PPAR-γ2 gene is therefore a promising 
candidate for metabolism syndrome [27]. 
Metabolic syndrome is the common name for 
a cluster of metabolic disorders that together 
represent an indicator of the risk for diabetes, 
heart disease, stroke and other cardiovascular 
conditions. This (MS) is characterized by a 
clustering of common chronic degenerative 
disorders such as hypertension, type 2 diabetes 
mellitus (T2DM), dyslipidaemia and obesity 
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[28], which has a strong genetic component. 
Variations in several candidate genes have 
been widely implicated in predisposing to 
these disorders. Peroxisome proliferator-
activated receptor gamma (PPAR-γ2), a 
nuclear hormone receptor, controls adipocyte 
differentiation and regulates a number of 
genes associated with energy homeostasis 
[29]. To date, at least two naturally occurring 
mutations in this gene have been identified, 
which impair the function of PPAR-γ2. The 
CG mutation (CCA-GCA missense Mutation) 
in exon B of the PPAR-γ2 gene leads to the 
substitution of alanine for proline at codon 12 
(Pro12Ala) which has been found to modulate 
the transcriptional activity of the gene [30].  
 
It has been clearly demonstrated that 
activation of PPAR-γ2 results in an increase in 
the sensitivity of both the liver to insulin-
mediated suppression of hepatic glucose 
production and insulin mediated skeletal 
muscle glucose uptake. In addition, PPAR-γ2 
ligands are also shown to augment glucose 
disposal in peripheral tissues by increasing 
expression of the glucose transporter genes 
glucose transporter 1 (GLUT1) and GLUT4 
[31,32]. Moreover, it has been suggested that 
the PPAR-γ2 gene affects the blood glucose 
level through enhancing insulin action on 
suppression of lipolysis, resulting in a 
decreased release of free fatty acids. 
Secondarily, reduced availability of free fatty 
acids would then permit muscle to utilize more 
glucose and liver to suppress glucose 
production more efficiently upon insulin 
stimulation.  
 
The effect of PPAR-γ2 Pro12 Ala 
polymorphism and association of T2DM has 
been investigated by different authors for 
different population. Most of the results 
demonstrate the pro allele to be associated 
with increased risk and the Ala allele with 
reduced risk for type 2 diabetic mellitus. The 
result of the present study also demonstrated 
that Ala allele showed slightly reduced risk as 
compared to the pro allele. The PPAR -12A 
polymorphism has been reported to have a 
protective role in diabetes type 2 risk [33–37] 
which is similar to the present study. Although 
findings have not been uniform [38–41], a 
meta-analysis by Altshuler et al. determined 
that the presence of the 12Ala allele confers 
about 20% reductions in risk for diabetes [37]. 
Radha et al. found that Pro allele is a genetic 
risk factor for type 2 diabetes mellitus in 
Caucasians but not in South Asians [42]. Thus, 
they suggested that population difference plays 
an important role in susceptibility to diabetes 
mellitus. Doney et al. [43] and Memisoglu et 
al. [44] also reported the association of pro 
allele frequency of PPAR- γ2 and type 2 
diabetes mellitus. Similarly another report 
showed that the pro allele of this gene may 
predispose to diabetic nephropathy [45].   
 
In contrast to this, Mancini et al. [46] and 
Ringel et al. failed to found a relationship 
between the pro 12 Ala polymorphism of 
PPAR-γ2 gene and type 2 diabetes mellitus, 
the reason described was small sample size 
could have lost the statistical power to show 
significant association. Moreover, genetic 
background difference also may play its own 
role for discrepancy. Apart from that, 
population difference may affect the role of 
Pro allele as a risk factor for type 2 diabetes 
mellitus by many theories such as; the genetic 
background because of the gene-gene 
interaction or nutrition habits, and life style 
may affect PPAR-γ2 ligands like oleic acid as 
reported by [47].  
 
A couple of reasons were the motives to 
conduct this study in a PPAR-γ 2 gene in north 
and south Gondar population. First, the 
majority of the genes identified thus far seem 
to affect diabetes susceptibility through cell 
dysfunction [48]. Second, the risk alleles tend 
to be common in the population, but their 
effect even if diabetes risk is relatively small 
[49]. However, this seemingly small risk 
association has not been studied ever since in 
the region and in the country due to varies 
reasons. Because recent genome-wide 
association (GWA) studies revealed 
convincing evidence for the contribution of 
genes to the pathogenesis of type 2 diabetes 
[50] and subsequent efforts in thoroughly and 
uniquely phenotyped cohorts provided first 
insights into these genes’ pathomechanistic 
roles [51].   
 
A wider study by including large sample size 
and area is warranted to confirm this 
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association further since; lack of resource has 
limited this study to concentrate on Gondar 
University, teaching hospital. 
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